Aethlon Medical Revenue and Competitors

Aethlon Medical develops therapeutic devices that treat HIV/AIDS, Hepatitis-C, and other infectious diseases. In pre-clinical testing, Aethlon's lead product, AEMD-45 removes 55% of HIV from human blood in three hours and in excess of 85% in twelve hours. The AEMD-45 therapeutic device, like all product offerings from Aethlon Medical, is developed from an expansive platform technology known as the Hemopurifier(TM), which employs a proprietary method to increase the capability of FDA cleared artificial kidneys (hemodialysis cartridges) to remove targeted intoxicants from the blood. In the case of AEMD-45, dialysis cartridges are modified to mimic the immune system's response to clear infectious virus from circulation before healthy cells are infected. AEMD-45 is designed to fill the urgent need for new treatments that are effective in reducing viral load, decrease the likelihood of treatment resistance, and treat without the toxic side-effects associated with AIDS drugs.